Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Capacity Building Assistance (CBA) To Improve the Delivery and Effectiveness of Human Immunodeficiency Virus (HIV) Prevention Services for High-Risk and/or Racial/Ethnicity Minority Populations, Program Announcement Number PS09-906, Initial Review, 46214 [E9-21510]

Download as PDF 46214 Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices V. Recommendation of Standards for Recognition by FDA Any person may recommend consensus standards as candidates for recognition under the new provision of section 514 of the act by submitting such recommendations, with reasons for the recommendation, to the contact person (See FOR FURTHER INFORMATION CONTACT). To be properly considered such recommendations should contain, at a minimum, the following information: (1) Title of the standard; (2) any reference number and date; (3) name and address of the national or international standards development organization; (4) a proposed list of devices for which a declaration of conformity to this standard should routinely apply; and (5) a brief identification of the testing or performance or other characteristics of the device(s) that would be addressed by a declaration of conformity. VI. Electronic Access You may obtain a copy of ‘‘Guidance on the Recognition and Use of Consensus Standards’’ by using the Internet. CDRH maintains a site on the Internet for easy access to information including text, graphics, and files that you may download to a personal computer with access to the Internet. Updated on a regular basis, the CDRH home page includes the guidance as well as the current list of recognized standards and other standards related documents. After publication in the Federal Register, this document announcing ‘‘Modification to the List of Recognized Standards, Recognition List Number: 022’’ will be available on the CDRH home page. You may access the CDRH home page at https://www.fda.gov/ cdrh. You may access ‘‘Guidance on the Recognition and Use of Consensus Standards,’’ and the searchable database for ‘‘FDA Recognized Consensus Standards’’ through the hyperlink at https://www.fda.gov/cdrh/stdsprog.html. This Federal Register document on modifications in FDA’s recognition of consensus standards is available at https://www.fda.gov/cdrh/fedregin.html. jlentini on DSKJ8SOYB1PROD with NOTICES VII. Submission of Comments and Effective Date Interested persons may submit to the contact person (see FOR FURTHER INFORMATION CONTACT) written or electronic comments regarding this document. Two copies of any mailed comments are to be submitted, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in VerDate Nov<24>2008 17:32 Sep 04, 2009 Jkt 217001 brackets in the heading of this document. FDA will consider any comments received in determining whether to amend the current listing of modifications to the list of recognized standards, Recognition List Number: 022. These modifications to the list or recognized standards are effective upon publication of this document in the Federal Register. Dated: August 26, 2009. Catherine M. Cook, Associate Director for Regulation and Policy. [FR Doc. E9–21609 Filed 9–4–09; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention (CDC) Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Capacity Building Assistance (CBA) To Improve the Delivery and Effectiveness of Human Immunodeficiency Virus (HIV) Prevention Services for High-Risk and/ or Racial/Ethnicity Minority Populations, Program Announcement Number PS09–906, Initial Review August 28, 2009. Correction: This notice was published in the Federal Register on August 6, 2009, Volume 74, Number 150, page 39333. The date on the original notice has changed. DATES: CONTACT PERSON FOR MORE INFORMATION: Monica Farmer, M.Ed., Public Health Analyst, Strategic Science and Program Unit, Office of the Director, Coordinating Center for Infectious Diseases, CDC, 1600 Clifton Road, NE., Mailstop E–60, Atlanta, GA 30333. Telephone (404) 498–2277. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: August 25, 2009. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E9–21510 Filed 9–4–09; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00135 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2009–N–0664] 2009 Parenteral Drug Association and Food and Drug Administration Joint Regulatory Conference AGENCY: Food and Drug Administration, HHS. ACTION: Notice of meeting. SUMMARY: The Food and Drug Administration (FDA) in co-sponsorship with the Parenteral Drug Association (PDA), is announcing a conference entitled ‘‘Securing the Future of Medical Product Quality: A 2020 Vision.’’ The workshop helps to achieve objectives set forth in the FDA Modernization Act of 1997, which include working closely with stakeholders and maximizing the availability and clarity of information to stakeholders and the public. Date and Time: The conference will be held on Monday, September 14, 2009 from 8 a.m. to 6 p.m.; Tuesday, September 15, 2009 from 7:15 a.m. to 5:45 p.m.; and Wednesday, September 16 from 7:15 a.m. to 1:15 p.m. Location: The public workshop will be held at the Renaissance Hotel, 999 9th St., Washington, D.C., 20001; 1– 202–898–9000; FAX: 1–202–289–0947. Contact: Regarding the conference: Wanda Neal, Parenteral Drug Association, PDA Global Headquarters, Bethesda Towers, 4350 East-West Hwy., suite 200, Bethesda, MD 20814. Regarding this document: Ken Nolan, Office of External Relations, Food and Drug Administration, 5600 Fishers Lane, rm. 15–05, Rockville, MD 20857, 301–827–3376. Registration: You are encouraged to register at your earliest convenience. The PDA registration fees cover the cost of facilities, materials, and breaks. Seats are limited; please submit your registration as soon as possible. Conference space will be filled in order of receipt of registration. Those accepted in to the conference will receive confirmation. Registration will close after applicable conference is filled. Onsite registration will be available on a space-available basis on the day of the public conference, beginning at 7 a.m. on Monday, September 14, 2009. The cost of registration is as follows: PDA Members ......... PDA Non-members Government ............ PDA Member Academic/Health Authority. E:\FR\FM\08SEN1.SGM 08SEN1 $1850.00 $2099.00 $700.00 $700.00

Agencies

[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Page 46214]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-21510]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel: Capacity Building Assistance (CBA) To Improve the 
Delivery and Effectiveness of Human Immunodeficiency Virus (HIV) 
Prevention Services for High-Risk and/or Racial/Ethnicity Minority 
Populations, Program Announcement Number PS09-906, Initial Review

DATES: August 28, 2009.
    Correction: This notice was published in the Federal Register on 
August 6, 2009, Volume 74, Number 150, page 39333. The date on the 
original notice has changed.

CONTACT PERSON FOR MORE INFORMATION: Monica Farmer, M.Ed., Public 
Health Analyst, Strategic Science and Program Unit, Office of the 
Director, Coordinating Center for Infectious Diseases, CDC, 1600 
Clifton Road, NE., Mailstop E-60, Atlanta, GA 30333. Telephone (404) 
498-2277.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both CDC and the Agency for Toxic Substances and Disease Registry.

    Dated: August 25, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E9-21510 Filed 9-4-09; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.